Comparative Study Between CHOP-Like Chemotherapy Plus Rituximab Versus CHOP-Like Chemotherapy Alone in Young Patients With Good Prognosis Diffuse Large-B-Cell Lymphoma
Background:The role of rituximab in combination with different CHOP
like chemotherapy regimens in young patients with good prognosis diffuse
large B cell lymphoma remains to be defined.
Aim: We aimed to compare CHOP like chemotherapy and rituximab with
CHOP like chemotherapy alone in patients with diffuse large B cell
lymphoma who had no risk factor or one risk factor regarding response,
progression free survival and over all survival as well as toxicity.
Materials and Methods: Eighty patients aged 18-60 years with
histologically confirmed diffuse large B cell lymphoma who had no risk
factor or one risk factor according to the age adjusted international
prognostic index were treated either with: group A treated CHOP
chemotherapy alone, group B treated with CHOP E (CHOP plus
Etoposide), group C treated with CHOP-R (CHOP plus rituximab), group
D treated with CHOP-E-R (CHOP plus Etoposid and retuximab).
Evaluation of response progression free survival over all survival as well as
Results: Patients treated with CHOP rituximab (CHOP-R) had better
response (86%) than those treated with CHOP alone or CHOP plus
etoposide (CHOP E) (83%, 85%) respectively but the difference between
the groups was not statistically significant. There was no statistical
significant difference between the studied groups regarding over all
survival 92% in group B, 93% in group C and 91% in group D.
Conclusions: Rituximab when added to six cycles of CHOP is an effective
treatment for young good prognosis diffuse large B cell lymphoma
however etoposide added to six cycles CHOP is also an effective treatment
for young good prong
Key words: CHOP: Cyclophosphamide, Doxorubicin Vircristine Prednisone
CHOEP: Cyclophosphamide, Doxorubicin Vircristine, Etoposide, Prednisone